Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand
Colman B. Taylor A B D and Michael Wonder C
+ Author Affiliations
- Author Affiliations
A The George Institute for Global Health–Critical Care and Trauma, PO Box M201 Missenden Road, Camperdown, NSW 2050, Australia.
B Sydney Medical School, Edward Ford Building A27, The University of Sydney, NSW 2006, Australia.
C Wonder Drug Consulting Pty Ltd, PO Box 470, Cronulla, NSW 2230, Australia. Email: wonderdrug@optusnet.com.au
D Corresponding author. Email: ctaylor@georgeinstitute.org.au
Australian Health Review 40(1) 120-120 https://doi.org/10.1071/AH15093
Submitted: 19 May 2015 Accepted: 26 May 2015 Published: 10 August 2015
References
[1] Ragupathy R, UD-Din-Babar Z. Comparing the reimbursement of new medicines between Australia and New Zealand. Aust Health Rev 2015;| Comparing the reimbursement of new medicines between Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar | 26189014PubMed |
[2] Taylor CB, Wonder M. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand. Aust Health Rev 2015;
| Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.Crossref | GoogleScholarGoogle Scholar |
[3] Lipworth W, Ho K, Kerridge I, Day R. Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency. Med J Aust 2012; 197 204–5.
| Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency.Crossref | GoogleScholarGoogle Scholar | 22900859PubMed |
